BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15279838)

  • 1. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
    Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
    Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
    Miyazaki M; Sugawara E; Yoshimura T; Yamazaki H; Kamataki T
    Mutat Res; 2005 Mar; 581(1-2):165-71. PubMed ID: 15725615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines.
    Suzuki A; Kushida H; Iwata H; Watanabe M; Nohmi T; Fujita K; Gonzalez FJ; Kamataki T
    Cancer Res; 1998 May; 58(9):1833-8. PubMed ID: 9581821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
    Shimada T; Hayes CL; Yamazaki H; Amin S; Hecht SS; Guengerich FP; Sutter TR
    Cancer Res; 1996 Jul; 56(13):2979-84. PubMed ID: 8674051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450.
    Muto S; Fujita K; Yamazaki Y; Kamataki T
    Mutat Res; 2001 Aug; 479(1-2):197-206. PubMed ID: 11470492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase.
    Oda Y; Aryal P; Terashita T; Gillam EM; Guengerich FP; Shimada T
    Mutat Res; 2001 May; 492(1-2):81-90. PubMed ID: 11377247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
    Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
    Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
    Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
    Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5.
    Kang IH; Kim HJ; Oh H; Park YI; Dong MS
    Mutat Res; 2004 Jan; 545(1-2):37-47. PubMed ID: 14698415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
    Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
    Mutat Res; 2000 Nov; 471(1-2):135-43. PubMed ID: 11080669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxic activation of 2-phenylbenzotriazole-type compounds by human cytochrome P4501A1 and N-acetyltransferase expressed in Salmonella typhimurium umu strains.
    Oda Y; Watanabe T; Terao Y; Nukaya H; Wakabayashi K
    Mutat Res; 2008 Jun; 654(1):52-7. PubMed ID: 18562244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new genotoxicity test system with Salmonella typhimurium OY1001/1A2 expressing human CYP1A2 and NADPH-P450 reductase.
    Aryal P; Yoshikawa K; Terashita T; Guengerich FP; Shimada T; Oda Y
    Mutat Res; 1999 Jun; 442(2):113-20. PubMed ID: 10393280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
    Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
    Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase and bacterial O-acetyltransferase in SOS/umu assay.
    Aryal P; Terashita T; Guengerich FP; Shimada T; Oda Y
    Environ Mol Mutagen; 2000; 36(2):121-6. PubMed ID: 11013410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxic activation of the environmental pollutant 3,6-dinitrobenzo[e]pyrene in Salmonella typhimurium umu strains expressing human cytochrome P450 and N-acetyltransferase.
    Oda Y; Hirayama T; Watanabe T
    Toxicol Lett; 2009 Aug; 188(3):258-62. PubMed ID: 19393727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin.
    Takahashi E; Fujita K; Kamataki T; Arimoto-Kobayashi S; Okamoto K; Negishi T
    Mutat Res; 2002 Oct; 508(1-2):147-56. PubMed ID: 12379470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.